The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder

Authors


Roger Dmochowski, Department of Urology, Medical Center North, Room A 1302, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
e-mail: roger.dmochowski@vanderbilt.edu

Abstract

OBJECTIVE

To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).

PATIENTS AND METHODS

We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (≥8 voids/24 h) and UUI (≥5 episodes/week) for ≥ 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.

RESULTS

Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.

CONCLUSIONS

These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.

Ancillary